NCT03675282View on ClinicalTrials.gov

Quantitative Mapping of Substantia Nigra Iron in Parkinson's Disease (Stages I-IV, REM Sleep Behavior Disorder) and Controls

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

August 14, 2018

Primary Completion Date

April 23, 2024

Study Completion Date

April 23, 2024

Conditions
Parkinson DiseaseREM Sleep Behavior DisorderHealthy
Interventions
DRUG

(11C)PE2I

Subjects will received (11C)PE2I PET Scans at Baseline and 24 Month Visits

DRUG

Ioflupane

Subjects will receive a DaT scan at baseline and 24 month visits if they don't receive a PE2I PET scan at baseline and 24 month visits

Trial Locations (1)

10021

Hospital for Special Surgery, New York

All Listed Sponsors
collaborator

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

lead

Weill Medical College of Cornell University

OTHER

NCT03675282 - Quantitative Mapping of Substantia Nigra Iron in Parkinson's Disease (Stages I-IV, REM Sleep Behavior Disorder) and Controls | Biotech Hunter | Biotech Hunter